BioCentury | Jan 31, 2018
Distillery Therapeutics


...testing other HIF1A stabilizers in additional models of heavy menstrual bleeding. Aerpio Pharmaceuticals Inc. has AKB-4924...
BioCentury | Oct 17, 2016
Clinical News

AKB-4924: Phase Ia started

...AKB-4924 in up to 48 healthy male volunteers. Aerpio Therapeutics Inc. , Cincinnati, Ohio Product: AKB-4924...
BioCentury | May 14, 2015
Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor 1α (HIF1A; HIF1-α)

...UTIs caused by uropathogenic Escherichia coli (UPEC). In UPEC-infected human uroepithelial cells, the HIF1A stabilizer AKB-4924...
...cell death compared with vehicle. In a mouse model of UPEC-associated UTI, pretreatment with transurethral AKB-4924... the bladder. Next steps could include developing oral formulations AKB-4924. Aerpio Therapeutics Inc. has AKB-4924...
BioCentury | Apr 16, 2012
Emerging Company Profile

Aerpio: Stanching the leak

...decided last fall to spin out the molecule and other preclinical programs. Aerpio also gained AKB-4924...
BioCentury | Jan 16, 2012
Company News

Akebia ophthalmic, autoimmune news

...macular edema (DME) next quarter, with data expected by year end. Aerpio's second compound is AKB-4924...
BioCentury | Jan 9, 2012

Project management make anti-VEGF drugs like Lucentis and Avastin obsolete." Aerpio also received a preclinical compound, AKB-4924...
Items per page:
1 - 6 of 6